Nanjing Chia-tai Tianqing Pharmaceutical

This early-stage trial tests a new drug called NTB003 in 74 people with thyroid eye disease, a condition that can cause bulging eyes and inflammation. Participants receive injections of NTB003 or a placebo every 4 weeks. The study measures whether the drug reduces eye bulging and…

This Phase 3 trial tests whether adding the experimental drug NTQ1062 to standard hormone therapy (fulvestrant) can slow or stop the growth of advanced HR+/HER2- breast cancer in people whose cancer has returned or worsened after hormone therapy. The study includes 210 adults wit…

This Phase 3 trial tests NTQ5082, an oral capsule, against the standard infusion eculizumab for paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. About 78 adults who have not had complement inhibitor therapy will be enrolled. The main goal is to see if NTQ5082 can…

This Phase 3 trial tests NTQ5082 capsules, a new drug that blocks a protein called CFB, in people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder that destroys red blood cells. The study will follow 78 adults who previously benefited from NTQ5082 or took ano…